GT200400266A - Un procedimiento de sintesis para la alquilacion reductiva en la posicion c-3 de los indoles que contienen gruposfuncionales sensibles al acido. - Google Patents

Un procedimiento de sintesis para la alquilacion reductiva en la posicion c-3 de los indoles que contienen gruposfuncionales sensibles al acido.

Info

Publication number
GT200400266A
GT200400266A GT200400266A GT200400266A GT200400266A GT 200400266 A GT200400266 A GT 200400266A GT 200400266 A GT200400266 A GT 200400266A GT 200400266 A GT200400266 A GT 200400266A GT 200400266 A GT200400266 A GT 200400266A
Authority
GT
Guatemala
Prior art keywords
acid
reductive
rental
functional groups
containing functional
Prior art date
Application number
GT200400266A
Other languages
English (en)
Inventor
Ronald S Michalak
Panolil Raveendranath
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT200400266A publication Critical patent/GT200400266A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/22—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an aralkyl radical attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

UN PROCEDIMIENTO DE ALQUILACION REDUCTIVA EN AL POSICION C3 DE UN COMPUESTO INDOL EN EL CUAL EL INDOL ES TRATADO CON UN ALDEHIDO EN LA PRESENCIA DE UN ACIDO DE LEWIS Y UN AGENTE REDUCTOR DE HIDRURO DE SILICIO. EL PROCEDIMIENTO ES UTIL PARA ALQUILAR LA POSICION C3 DE LOS INDOLES QUE CONTIENEN SUBSTITUYENTES SENSIBLES AL ACIDO EN LA POSICION N1.
GT200400266A 2003-12-16 2004-12-14 Un procedimiento de sintesis para la alquilacion reductiva en la posicion c-3 de los indoles que contienen gruposfuncionales sensibles al acido. GT200400266A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US52979703P 2003-12-16 2003-12-16

Publications (1)

Publication Number Publication Date
GT200400266A true GT200400266A (es) 2005-08-30

Family

ID=34700047

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200400266A GT200400266A (es) 2003-12-16 2004-12-14 Un procedimiento de sintesis para la alquilacion reductiva en la posicion c-3 de los indoles que contienen gruposfuncionales sensibles al acido.

Country Status (26)

Country Link
US (2) US7282594B2 (es)
EP (1) EP1697320B1 (es)
JP (1) JP5121232B2 (es)
KR (2) KR101194592B1 (es)
CN (1) CN1914170B (es)
AR (1) AR046895A1 (es)
AU (1) AU2004299462B2 (es)
BR (1) BRPI0417769B8 (es)
CA (1) CA2549120C (es)
CR (1) CR8446A (es)
EC (1) ECSP066648A (es)
EG (1) EG24473A (es)
GT (1) GT200400266A (es)
HN (1) HN2004000536A (es)
IL (1) IL176147A (es)
MX (1) MXPA06006669A (es)
NI (1) NI200600132A (es)
NO (1) NO20062757L (es)
PA (1) PA8620101A1 (es)
PE (1) PE20051012A1 (es)
RU (1) RU2352560C2 (es)
SG (1) SG147487A1 (es)
TW (1) TW200526576A (es)
UA (1) UA84445C2 (es)
WO (1) WO2005058820A1 (es)
ZA (1) ZA200604966B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7713964B2 (en) 2001-12-03 2010-05-11 Wyeth Llc Methods for treating asthmatic conditions
US7605156B2 (en) 2001-12-03 2009-10-20 Wyeth Methods for the use of inhibitors of cytosolic phospholipase A2
TW200510305A (en) * 2003-07-25 2005-03-16 Wyeth Corp Process for the preparation of CPLA2 inhibitors
US7582771B2 (en) * 2003-09-03 2009-09-01 Wyeth Process for the synthesis of cPLA2 inhibitors
US7342119B2 (en) * 2003-09-30 2008-03-11 Wyeth Holdings Corporation Process for the synthesis of a CPLA2 inhibitor
AR053410A1 (es) * 2004-08-19 2007-05-09 Wyeth Corp Proceso para la sintesis de indoles n-alquilados c-2, c-3 sustituidos. compuestos intermediarios
TW200718687A (en) 2005-05-27 2007-05-16 Wyeth Corp Inhibitors of cytosolic phospholipase A2
US20100113443A1 (en) * 2006-10-31 2010-05-06 Wyeth Liquid formulations of phospholipase enzyme inhibitors
TW200826932A (en) * 2006-10-31 2008-07-01 Wyeth Corp Semi-solid formulations of phospholipase enzyme inhibitors
CN111087340B (zh) * 2019-11-29 2021-12-07 上海应用技术大学 一种维拉佐酮中间体的制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9317764D0 (en) 1993-08-26 1993-10-13 Pfizer Ltd Therapeutic compound
GB9609641D0 (en) * 1996-05-09 1996-07-10 Pfizer Ltd Compounds useful in therapy
US6635771B2 (en) * 2001-12-03 2003-10-21 Wyeth N-benzhydryl indole compounds
KR100973665B1 (ko) * 2001-12-03 2010-08-04 와이어쓰 엘엘씨 세포질 포스포리파제 ａ2의 억제제
US7713964B2 (en) * 2001-12-03 2010-05-11 Wyeth Llc Methods for treating asthmatic conditions
US7605156B2 (en) 2001-12-03 2009-10-20 Wyeth Methods for the use of inhibitors of cytosolic phospholipase A2
US6797708B2 (en) * 2001-12-03 2004-09-28 Wyeth Inhibitors of cytosolic phospholipase A2
US6984735B2 (en) * 2001-12-03 2006-01-10 Wyeth Process for making an aldehyde
US7101875B2 (en) * 2001-12-03 2006-09-05 Wyeth Methods for treating arthritic disorders
US20040182785A1 (en) * 2002-10-23 2004-09-23 Rigel Technology Corporation Animal plasma process by precipitation
TW200510305A (en) 2003-07-25 2005-03-16 Wyeth Corp Process for the preparation of CPLA2 inhibitors
US7582771B2 (en) 2003-09-03 2009-09-01 Wyeth Process for the synthesis of cPLA2 inhibitors
US7342119B2 (en) * 2003-09-30 2008-03-11 Wyeth Holdings Corporation Process for the synthesis of a CPLA2 inhibitor
AR053410A1 (es) 2004-08-19 2007-05-09 Wyeth Corp Proceso para la sintesis de indoles n-alquilados c-2, c-3 sustituidos. compuestos intermediarios
TW200718687A (en) 2005-05-27 2007-05-16 Wyeth Corp Inhibitors of cytosolic phospholipase A2

Also Published As

Publication number Publication date
BRPI0417769B1 (pt) 2019-12-17
NI200600132A (es) 2007-01-17
EP1697320A1 (en) 2006-09-06
US20080161581A1 (en) 2008-07-03
CR8446A (es) 2006-12-07
KR101194592B1 (ko) 2012-10-25
UA84445C2 (ru) 2008-10-27
AU2004299462B2 (en) 2011-07-14
RU2352560C2 (ru) 2009-04-20
CN1914170B (zh) 2010-07-14
PA8620101A1 (es) 2006-03-24
AR046895A1 (es) 2005-12-28
AU2004299462A1 (en) 2005-06-30
CN1914170A (zh) 2007-02-14
KR20120082477A (ko) 2012-07-23
TW200526576A (en) 2005-08-16
US7282594B2 (en) 2007-10-16
NO20062757L (no) 2006-06-28
BRPI0417769B8 (pt) 2021-05-25
BRPI0417769A8 (pt) 2018-05-08
IL176147A (en) 2011-12-29
SG147487A1 (en) 2008-11-28
IL176147A0 (en) 2006-10-05
CA2549120C (en) 2012-06-26
ZA200604966B (en) 2010-11-24
RU2006125447A (ru) 2008-01-27
BRPI0417769A (pt) 2007-04-17
EP1697320B1 (en) 2013-04-10
JP2007514004A (ja) 2007-05-31
KR20070018820A (ko) 2007-02-14
HN2004000536A (es) 2009-02-18
CA2549120A1 (en) 2005-06-30
JP5121232B2 (ja) 2013-01-16
MXPA06006669A (es) 2006-08-11
PE20051012A1 (es) 2006-01-13
EG24473A (en) 2009-08-03
US7709661B2 (en) 2010-05-04
US20050148770A1 (en) 2005-07-07
WO2005058820A1 (en) 2005-06-30
ECSP066648A (es) 2006-10-25

Similar Documents

Publication Publication Date Title
ECSP066648A (es) Metodologia sintetica para la alquilacion reductiva en la posicion c-3 de indoles
CR11220A (es) Derivados de pirimidina 934
ES2422204T3 (es) Novedosos derivados de imidazolidin-2-ona como moduladores selectivos de receptor de andrógenos (SARMS)
WO2003106628A3 (en) BENZFIAZEPINE F1F0 ATP HYDROLASE MITOCHONDRIAL INHIBITORS AND METHODS OF INHIBITING F1F0 ATP HYDROLASE
DE502006006854D1 (de) Substituierte benzo (d) isoaxol-3-yl-amin-verbindungen als analgetika
AR045234A1 (es) Metodo para producir derivados del almidon de hidroxialquilo y composiciones farmaceuticas que los contienen.
ES2220529T3 (es) Dibenzopiranos utiles como antagonistas del receptor de los glucocorticoides, en el tratamiento de la diabetes.
CO6220949A2 (es) Derivados pirazolicos como inhibidores de la 11 beta -hsd1
HRP20130800T1 (en) Opioid receptor modulators
PE20040165A1 (es) Uso de analogos del benzimidazol en el tratamiento de la proliferacion celular
DE602004011348D1 (de) Indanderivate als muscarinrezeptoragonisten
PA8791601A1 (es) Compuestos de biciclolactama sustituida
DE602004023207D1 (de) Benzimidazol-derivate als mek-hemmer
CR11245A (es) Mejoras en compuestos organicos o relacionadas con los mismos
CO5160250A1 (es) Derivados de piridopiranoacepinas su procedimiento de sintesis y composiciones que los contienen
AR059216A1 (es) 11b-hidroxiandrosta-4-eno-3-onas
DE60306398D1 (de) Gasgenerator
NI201000049A (es) Método para producir 2'-desoxi-5-azacitidina (decitabina)
HN2008001934A (es) 18-metil-19-nor-androst-4-en-17,17-espiroesteres (18-metil-19-nor-20-espirox-4-en-3-onas), asi como preparaciones farmaceuticas que los contienen.
BR0113610A (pt) Derivados da fenoxibenzilamina como inibidores seletivos de recuperação de serotonina
GT200600334A (es) Proceso para la sintesis de los moduladores del receptor de progesterona
EA200601079A1 (ru) Способы защиты от радиации с использованием флагеллина
ECSP034531A (es) Derivados sustituidos de c-ciclohexilmetilamina
ECSP045027A (es) Agonistas muscarinicos
AR065393A1 (es) Derivados de indol como agonistas del receptor de canabinoides cb1, y su uso en el tratamiento del dolor